13F

Stock

PharmaCyte Biotech, Inc.

PMCB · held by 30 managers

Reported value

$580.1K

Holders

30

+0 new · −0 exited

Holders’ est. mark

−$78

Price effect on 3 books still in the name

Largest holder

$166.3K

Citadel

Notable conviction

Share of each notable manager’s 13F book.

Holder count by quarter

Who holds it

Notable only
InvestorSharesValueEst. markChange
Citadel229.7K$166.3KHeld
GEODE CAPITAL MANAGEMENT, LLC123.8K$89.7KHeld
SABBY MANAGEMENT, LLC100K$72.4KHeld
Renaissance Technologies94K$68.1KHeld
Vanguard74.9K$54.2KHeld
NORTHERN TRUST CORP35.6K$25.8KHeld
Schonfeld Strategic Advisors LLC26.2K$19KHeld
SIMPLEX TRADING, LLC25.8K$18.7KHeld
TWO SIGMA SECURITIES, LLC24.6K$17.8KHeld
XTX Topco Ltd24.4K$17.7KHeld
EQUITEC PROPRIETARY MARKETS, LLC22.2K$16.1KHeld
JANE STREET GROUP, LLC11.4K$8.25KHeld
Tower Research Capital LLC (TRC)4.9K$3.55KHeld
UBS Group AG2.75K$1.99KHeld
BANK OF AMERICA CORP /DE/314$227−$78Cut−$295
OSAIC HOLDINGS, INC.303$219Held
HRT FINANCIAL LP182.8K$132Held
Sachetta, LLC14$11Held
Aviso Financial Inc.12$8Held
BFSG, LLC5$4Held
FINANCIAL CONSULATE, INC2$2Held
MORGAN STANLEY2$2−$0Cut−$8
BlackRock, Inc.1$1Held
MCF Advisors LLC1$1Held
NewEdge Advisors, LLC2$1Held
IFP Advisors, Inc1$1$0Held
CALDWELL SUTTER CAPITAL, INC.2$1Held
CWM, LLC1$0Held
HUNTINGTON NATIONAL BANK1$0Held
Covestor Ltd275$0Held

Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.